1,643
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Localized Peripheral Neuropathic Pain: Topical Treatment with Lidocaine 700 mg Medicated Plaster in Routine Clinical Practice

ORCID Icon, , , & ORCID Icon
Pages 521-533 | Received 28 Nov 2021, Accepted 22 Dec 2021, Published online: 10 Jan 2022

References

  • Scholz J , FinnerupNB , AttalNet al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain160, 53–59 (2019).
  • Casale R , MattiaC. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster. Ther. Clin. Risk Manage.10, 259–268 (2014).
  • Mick G , BaronR , FinnerupNBet al. What is localized neuropathic pain? A first proposal to characterise and define a widely used term. Pain Manage.2, 71–77 (2012).
  • Mick G , SerpellM , BaronRet al. Localised neuropathic pain in the primary care setting: a cross-sectional study of prevalence, clinical characteristics, treatment patterns, quality of life and sleep performance. Curr. Med. Res. Opin.37, 293–302 (2021).
  • Van Acker K , BouhassiraD , DeBacquer Det al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab.35, 206–213 (2009).
  • Serpell M , GaterA , CarrollSet al. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study. Health Qual. Life Outcomes.12, 92 (2014).
  • Attal N , CruccuG , BaronRet al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol.17, 1113–e1188 (2010).
  • Finnerup NB , AttalN , HaroutounianSet al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol.14, 162–173 (2015).
  • Allegri M , BaronR , HansGet al. A pharmacological treatment algorithm for localized neuropathic pain. Curr. Med. Res. Opin.32, 377–384 (2016).
  • de León-Casasola OA , MayoralV. The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence. J. Pain Res.9, 67–79 (2016).
  • Baron R , AllegriM , Correa-IllanesGet al. The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther.5, 149–169 (2016).
  • Cave A , KurzX , ArlettP. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin. Pharm. Ther.106, 36–39 (2019).
  • Bolislis WR , FayM , KühlerTC. Use of real-world data for new drug applications and line extensions. Clin. Ther.42, 926–938 (2020).
  • Überall MA , EerdekensM , BöslIet al. Lidocaine 700mg medicated plaster for postherpetic neuralgia: real-world data from the German Pain e-Registry. Pain Manage. (2021) ( Epub ahead of print).
  • German Society of Neurology ; SchlerethTet al.Diagnosis and noninterventional treatment of neuropathic pain, S2k guideline (in German), 2019. In: Guidelines for Diagnosis and Treatment in Neurology.www.awmf.org/uploads/tx_szleitlinien/030-114l_S2k_Diagnose-nicht-interventionelle-Therapie-neuropathischer-Schmerzen_2020-04_1.pdf
  • German Pain Society . Manual for the German pain questionnaire (in German). www.schmerzgesellschaft.de/fileadmin/pdf/DSF_Handbuch_2020.pdf
  • von Korff M , OrmelJ , KeefeFJ , DworkinSF. Grading the severity of chronic pain. Pain50, 133–149 (1992).
  • Schmitt N , GerbershagenHU. The Mainz Staging System (MPSS) for chronic pain. Pain41(Suppl. 5), S484 (1990).
  • Tait RC , ChibnallJT , KrauseS. The pain disability index: psychometric properties. Pain40, 171–182 (1990).
  • Hayes CJ , BhandariNR , KatheN , PayakachatN. Reliability and validity of the medical outcomes study short form-12 version 2 (SF-12v2) in adults with non-cancer pain. Healthcare (Basel)5, 22 (2017).
  • Cappelleri JC , BienenEJ , KoduruV , SadoskyA. Measurement properties of painDETECT by average pain severity. Clinicoecon. Outcomes Res.6, 497–504 (2014).
  • Guy W . ECDEU Assessment Manual for Psychopharmacology (DHEW Publication no. ADM 76-338).US Government Printing Office, DC, USA (1976).
  • Mick G , Correa-IllanesG. Topical pain management with the 5% lidocaine medicated plaster – a review. Curr. Med. Res. Opin.28, 937–951 (2012).
  • Delorme C , NavezML , LegoutVet al. Treatment of neuropathic pain with 5% lidocaine-medicated plaster: five years of clinical experience. Pain Res. Manage.16, 259–263 (2011).
  • Martini A , DelBalzo G , SchweigerVet al. Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. Minerva Medica109, 344–351 (2018).
  • Correa-Illanes G , CalderónW , RoaRet al. Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local Regional Anesth.3, 77–83 (2010).
  • Casale R , MatteoMD , MinellaCEet al. Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series. J. Pain Res.7, 353–357 (2014).
  • Amato F , DuseG , ConsolettiLet al. Efficacy and safety of 5% lidocaine-medicated plasters in localized pain with neuropathic and/or inflammatory characteristics: an observational, real-world study. Eur. Rev. Med. Pharmacol. Sci.21, 4228–4235 (2017).
  • Wolff RF , BalaMM , WestwoodM , KesselsAG , KleijnenJ. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol. Scand.123, 295–309 (2011).
  • Buksnys T , ArmstrongN , WorthyGet al. Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin. Curr. Med. Res. Opin.36, 101–115 (2020).
  • Navez ML , MonellaC , BöslIet al. 5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther.4, 1–15 (2015).
  • Katz P , PegoraroV , LiedgensH. Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe – the role of the lidocaine 5% medicated plaster. Curr. Med. Res. Opin.33, 1481–1489 (2017).
  • Sansone P , PassavantiMB , FiorelliAet al. Efficacy of the topical 5% lidocaine medicated plaster in the treatment of chronic post-thoracotomy neuropathic pain. Pain Manage.7, 189–196 (2017).
  • Pickering G , VouteM , MacianNet al. Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery: a randomized, double-blind controlled trial. Pain160, 1186–1195 (2019).
  • Palladini M , BoeslI , KoenigSet al. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial. Curr. Med. Res. Opin.35, 757–766 (2019).
  • Schubert T , KernKU , SchneiderS , BaronR. Oral or topical pain therapy – how would patients decide? A discrete choice experiment in patients with peripheral neuropathic pain. Pain Pract.21, 536–546 (2021).